SINOPHARM(01099)2024-04-07 16:00Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 30.9, indicating a potential upside of 51.8% from the current price of HKD 20.35 [3][4]. Core Insights - The company reported a revenue of RMB 596.57 billion for 2023, reflecting an 8.1% year-on-year growth. The net profit increased by 4.6% to RMB 15.01 billion, with shareholder equity rising by 6.2% to RMB 9.05 billion [2][3]. - The overall gross margin has declined by 0.5 percentage points to 8.1%, while the company has effectively controlled expenses, leading to a decrease in distribution and administrative expense ratios [2][3]. - The pharmaceutical distribution segment generated RMB 441.05 billion in revenue, up 8.5%, while the medical device segment grew by 7.8% to RMB 130.21 billion [2][3]. Financial Summary - Revenue projections show a steady increase from RMB 639.73 billion in 2024E to RMB 724.44 billion in 2026E, with annual growth rates ranging from 6.3% to 8.0% [5]. - Net profit is expected to rise from RMB 9.50 billion in 2024E to RMB 10.79 billion in 2026E, with a consistent growth trajectory [5]. - Earnings per share (EPS) is projected to grow from RMB 3.05 in 2024E to RMB 3.46 in 2026E, reflecting a positive outlook for shareholder returns [5]. Segment Performance - The pharmaceutical distribution segment remains the largest contributor, accounting for 71.4% of total revenue, while the medical device and retail segments contribute 21.1% and 5.8%, respectively [2][3]. - The medical device segment is expected to gain traction with new partnerships and product launches, including a joint venture with GE Healthcare [3]. - The retail pharmacy segment has shown improvement, with a 0.73 percentage point increase in operating profit margin to 3.21% and an increase in the number of retail outlets [3].